|
|
Carfilzomib up front? Bortezomib schedule?Carfilzomib up front? Bortezomib schedule?a. In what situations, if any, would you consider administering carfilzomib (CRd or CyCd) as induction therapy for transplant-eligible patients with MM? b. When using bortezomib as part of a triplet induction-therapy regimen (eg, RVD, CyBorD) for younger, transplant-eligible patients with MM, what schedule and method of administration do you generally use?
Bringhen S et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: A multicenter, phase 2 study. Blood 2014;124(1):63-9. Abstract Clinical experience, tolerability and side effects of carfilzomib, alone or in combination, in newly diagnosed and relapsed/refractory MM. Available at: http://www.researchtopractice.com/HOU113/sagar-lonial-md/clinical-experience-tolerability-and-side-effects-carfilzomib-alone-or-comb-0. Korde N et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone (CRd) in newly diagnosed multiple myeloma (MM) patients. Proc ASH 2012;Abstract 732. Mateos MV et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial. Lancet Oncol 2010;11(10):934-41. Abstract Moreau P et al. Bortezomib-thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Br J Haematol 2014;[Epub ahead of print]. Abstract Sonneveld P et al. Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: Extended follow-up of the HOVON-65/GMMG-HD4 trial. Proc ASH 2013;Abstract 404. |